Abstract B091: Establishment and characterization of a panel of naive and pretreated brain cancer XPDX models
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-b091
Abstract: The survival rate of aggressive brain cancers like glioblastoma averages less than eighteen months with few treatment options. However, advances in molecular testing have identified novel cancer drivers leading to the development of new therapies.… read more here.
Keywords: xpdx models; cancer; panel; brain ... See more keywords
Abstract 3869: Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3869
Abstract: Background: Mechanisms of resistance to CDK4/6 inhibitors (CDK4/6i) have been well studied and several alterations identified including RB loss and altered expression of related genes including CCNE1, E2F4 and CDK6. However, whether duration of clinical… read more here.
Keywords: resistance; cdk4; treatment; xpdx models ... See more keywords
Abstract PO1-26-03: Activity of alpelisib in a panel of breast XPDX models harboring hotspot and uncommon PIK3CA mutations
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po1-26-03
Abstract: Background: Therapies targeting mutated phosphoinositide 3-kinase (PI3K) p110α catalytic subunit (PIK3CA) cancers remain an active field of research. Alpelisib was approved in combination with fulvestrant in ER+/HER2- breast cancer patients harboring PIK3CA mutations on hotspot… read more here.
Keywords: xpdx models; cancer; breast; pik3ca ... See more keywords
Abstract P3-02-20: CDK4/6 inhibitor resistance in patients with ER+ breast cancer: Identification and characterization of resistance mechanisms in thirty-two XPDX models
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p3-02-20
Abstract: Background: Resistance to CDK4/6 inhibitors (CDK4/6i) has been well studied with several mechanisms identified, including loss of RB, FAT1, and ERa and altered expression of regulatory genes such as CCND1, CCNE1/2, and CDK2. Additionally, alterations… read more here.
Keywords: xpdx models; cancer; resistance; breast ... See more keywords